SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-24-007196
Filing Date
2024-05-08
Accepted
2024-05-08 08:00:14
Documents
15
Period of Report
2024-05-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K avbp-20240508x8k.htm   iXBRL 8-K 40525
2 EX-99.1 avbp-20240508xex99d1.htm EX-99.1 155581
3 GRAPHIC avbp-20240508xex99d1002.jpg GRAPHIC 5662
  Complete submission text file 0001558370-24-007196.txt   340799

Data Files

Seq Description Document Type Size
4 EX-101.SCH avbp-20240508.xsd EX-101.SCH 3394
5 EX-101.LAB avbp-20240508_lab.xml EX-101.LAB 16576
6 EX-101.PRE avbp-20240508_pre.xml EX-101.PRE 10709
18 EXTRACTED XBRL INSTANCE DOCUMENT avbp-20240508x8k_htm.xml XML 5009
Mailing Address 18 CAMPUS BLVD. SUITE 100 NEWTOWN SQUARE PA 19073-3269
Business Address 18 CAMPUS BLVD. SUITE 100 NEWTOWN SQUARE PA 19073-3269 240-780-6356
ArriVent BioPharma, Inc. (Filer) CIK: 0001868279 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41929 | Film No.: 24924295
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)